IGF-II Receptor Gene Copy Number in Breast Cancer
Author Information
Author(s): E. Hebert, C. Herbelin, P. Bougnoux
Primary Institution: Centre de Biophysique Moleculaire et Universite d'Orleans; Laboratoire de Biologie des Tumeurs, Universite de Tours
Hypothesis
Is the Man-6-P/IGF-II receptor gene copy number altered in breast cancer?
Conclusion
The IGF-II receptor gene is stable in breast carcinoma and its involvement in cancer progression may be due to changes in its expression rather than gene amplification.
Supporting Evidence
- The study found no amplification of the Man-6-P/IGF-II receptor gene in any of the 51 breast cancer specimens analyzed.
- The receptor gene is transcribed in both tumor and non-tumor breast tissues.
- Amplification of other genes like c-erbB2 and int-2 was observed in some tumors, indicating heterogeneity in breast cancer.
Takeaway
The study looked at breast cancer samples to see if a specific gene was copied more than normal, but they found it wasn't, suggesting the gene works differently in cancer.
Methodology
Southern blotting was used to analyze the gene copy number in breast cancer specimens.
Potential Biases
The sample selection may not fully represent early-stage tumors.
Limitations
The study may have a selection bias towards larger tumors due to the need for adequate material for analysis.
Participant Demographics
The majority of tumors were of the ductal type, with a mix of lobular and other types.
Want to read the original?
Access the complete publication on the publisher's website